Close Menu

NEW YORK – Roche said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination of atezolizumab (Roche's Tecentriq) plus chemotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression greater than a percent and who have not previously received chemotherapy for metastatic disease.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.